PA01.72. Evaluation of DB14201 on prevention of development of streptozotocin induced diabetes mellitus in wistar rats

Purpose:

Study is part of an ongoing reverse pharmacology approach in new drug development for diabetes. It was designed to determine the potential of DB14201 to prevent the development of Streptozotocin induced Diabetes Mellitus in Wistar rats.

Method:

35 female Wistar rats were randomized and allocated to different groups on the basis of body weight. G1 served as non diabetic control (Negative Control) and G2 served as Diabetic control (Vehicle Control) and received 10 ml/kg of Milli Q water. G3 and G4 were treated with 500mg/kg and 250mg/kg of DB14201 respectively. All the groups were treated orally for 21 days using disposable syringes tipped with an oral gavage needle. At the end of dosing period, hyperglycemia was induced in G2,G3 and G4 rats by intra peritoneal injection of streptozotocin (STZ) 55 mg/kg in citrate buffer (pH 4.5). Fasting blood glucose level was estimated before induction of diabetes and on 2nd & 7th days post induction. All animals were observed daily for mortality and clinical signs of toxicity throughout the experimental period. Body weight of each animal was recorded daily throughout the experimental period. On the 8th day post STZ injection, animals were killed by cervical dislocation. Their pancreatic tissues were quickly removed. Tissues were washed in normal saline and visible clots were removed to minimize blood contamination. Part of the pancreatic tissue was sent for histological evaluation. With second part of tissue, homogenates was prepared and stored at 70 A°C until the determination of biochemical parameters and enzyme activity.

Result:

Findings of this study strongly demonstrate that DB14201 treatment have prominent role in the prevention of STZ induced diabetes mellitus.

Conclusion:

Result clearly indicates the prophylactic as well as therapeutic potential of DB14201 in this experimental model. DB14201 at the dose of 500mg/kg was found to be more promising.

PA01.79. Effect of DB 14201 on experimentally induced uncontrolled Diabetes in wistar rats

Purpose:

Study is part of an ongoing reverse pharmacology approach in new drug development for diabetes. It was designed to determine the effect of DB14201 on experimentally induced uncontrolled diabetes in male Wistar rats.

Method:

The rats were divided in eight groups namely, (G1) Non diabetic control, (G2) diabetic control, (G3) test item 250mg/kg, (G4) test item 500 mg/kg, (G5) Metformin 500 mg/kg, (G6) Metformin 250 mg/kg, (G7) combination of T.I (250 mg/kg) and Metformin (250mg/kg) and (G8) combination of T.I (500 mg/kg) and Metformin (250mg/kg). All groups had 10 animals each except G1, the non diabetic vehicle control group, which had 5 animals. Hyperglycemia was induced in the all the animals (except G1) by intraperitoneal injection of STZ at the dose of 65mg/kg. Seven days post STZ induction; all the groups were treated orally with respective study materials for 21 days using disposable syringes tipped with an oral gavage needle. Blood glucose level, body weight, toxic signs and survival rate of animal was recorded throughout the dosing period.

Result:

Amongst all the DB14201 treated groups, G& i.e, combination of Metformin 250mg/kg and DB14201 250mg/kg showed maximum efficacy in lowering blood glucose level. However in the same group mortality rate was high. The body weight change throughout the study was not significant (<20%) in all the groups, which nullifies any drug related toxicity. Remarkable elevation of triglyceride levels in the diabetes induced groups give the evidence of uncontrolled diabetes. G3 i.e. DB14201 250mg/kg showed maximum survival rate at the end of the study. The relative survival percentage in this group was 150, which is the highest among the treatment groups.

Conclusion:

The finding of this study indicates that the test item DB14201 (250 mg/kg) is could be highly effective in terminal stage diabetes in increasing the survival rate.